Morphelan™ Will ContributeSignificant Value to our LSPP Portfolio

Will form new sales force to target general

pain centers not served by existing reps

True once-daily dosing, unique dual-release formulation, comparatively smooth PK profile

U.S. sustained-release opioid market is $2.3 billion, largest initial market we’ve entered

Elan has announced interest to co-promote in U.S.

Previous slide

Next slide

Back to first slide

View graphic version